Your browser doesn't support javascript.
loading
Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study.
Hoff, Leonardo Santos; Naveen, R; Sen, Parikshit; Day, Jessica; Joshi, Mrudula; Nune, Arvind; Nikiphorou, Elena; Saha, Sreoshy; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Velikova, Tsvetelina; Milchert, Marcin; Jagtap, Kshitij; Parodis, Ioannis; Edgar Gracia-Ramos, Abraham; Cavagna, Lorenzo; Kuwana, Masataka; Knitza, Johannes; Chen, Yi Ming; Makol, Ashima; Agarwal, Vishwesh; Patel, Aarat; Pauling, John D; Wincup, Chris; Barman, Bhupen; Zamora Tehozol, Erick Adrian; Rojas Serrano, Jorge; García-De La Torre, Ignacio; Colunga-Pedraza, Iris J; Merayo-Chalico, Javier; Chibuzo, Okwara Celestine; Katchamart, Wanruchada; Akarawatcharangura Goo, Phonpen; Shumnalieva, Russka; El Kibbi, Lina; Halabi, Hussein; Vaidya, Binit; Shaharir, Syahrul Sazliyana; Hasan, A T M Tanveer; Dey, Dzifa; Toro Gutiérrez, Carlos Enrique; Caballero-Uribe, Carlo V; Lilleker, James B; Salim, Babur; Gheita, Tamer; Chatterjee, Tulika; Distler, Oliver; Saavedra, Miguel A; Chinoy, Hector.
Afiliación
  • Hoff LS; School of Medicine, Universidade Potiguar (UnP), Natal, Brazil.
  • Naveen R; Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • Sen P; Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-, 110002, India.
  • Day J; Department of Rheumatology, Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
  • Joshi M; Walter, Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australiaand.
  • Nune A; Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia.
  • Nikiphorou E; Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
  • Saha S; Southport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, UK.
  • Tan AL; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Shinjo SK; Rheumatology Department, King's College Hospital, London, UK.
  • Ziade N; Mymensingh Medical College, Mymensingh, Bangladesh.
  • Velikova T; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
  • Milchert M; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Jagtap K; Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
  • Parodis I; Rheumatology Department, Saint-Joseph University, Beirut, Lebanon.
  • Edgar Gracia-Ramos A; Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
  • Cavagna L; Medical Faculty, Sofia University St Kliment Ohridski, 1 Kozyak Str, Sofia, 1407, Bulgaria.
  • Kuwana M; Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, ul Unii Lubelskiej 1, 71-252, Szczecin, Poland.
  • Knitza J; Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, Maharashtra, India.
  • Chen YM; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Makol A; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Agarwal V; Department of Internal Medicine, General Hospital, National Medical Center, La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, Mexico City, C.P., 02990, Mexico".
  • Patel A; Rheumatology Unit, Dipartimento di Medicine Interna e Terapia Medica, Università degli studi di Pavia, Pavia, Lombardy, Italy.
  • Pauling JD; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
  • Wincup C; Medizinische Klinik 3-Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, Erlangen, 91054, Deutschland.
  • Barman B; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan.
  • Zamora Tehozol EA; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Rojas Serrano J; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
  • García-De La Torre I; Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India.
  • Colunga-Pedraza IJ; Bon Secours Rheumatology Center and Division of Pediatric Rheumatology, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Merayo-Chalico J; Bristol Medical School Translational Health Sciences, University of Bristol, UK.
  • Chibuzo OC; Department of Rheumatology, North Bristol NHS Trust, Bristol, UK.
  • Katchamart W; Department of Rheumatology, Division of Medicine, Rayne Institute, University College London, UK.
  • Akarawatcharangura Goo P; Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, GOSH, London, UK.
  • Shumnalieva R; Walter, Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australiaand.
  • El Kibbi L; Rheumatology, Medical Care & Research, Centro Medico Pensiones Hospital, Instituto Mexicano del Seguro Social Delegación Yucatán, Yucatán, Mexcio.
  • Halabi H; Rheumatologist and Clinical Investigator, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
  • Vaidya B; Departamento de Inmunología y Reumatología, Hospital General de Occidente and Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
  • Shaharir SS; Rheumatology, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico.
  • Hasan ATMT; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Dey D; Department of Medicine, University of Nigeria Teaching Hospital, Ituku-Ozalla/University of Nigeria, Enugu Campus, Enugu, Nigeria.
  • Toro Gutiérrez CE; Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Caballero-Uribe CV; Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand.
  • Lilleker JB; Department of Rheumatology, Clinic of Rheumatology, University Hospital "St Ivan Rilski", Medical University-Sofia, Bulgaria.
  • Salim B; Rheumatology Unit, Internal Medicine Department, Specialized Medical Center, Riyadh, Saudi Arabia.
  • Gheita T; Department of Internal Medicine, Section of rheumatology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Chatterjee T; National Center for Rheumatic Diseases (NCRD), Ratopul, Kathmandu, Nepal.
  • Distler O; Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, 56000.
  • Saavedra MA; Department of Rheumatology, Enam Medical College & Hospital, Dhaka, Bangladesh.
  • Chinoy H; General Director, Reference Center for Osteoporosis, Rheumatology and Dermatology, Pontifica Universidad Javeriana Cali, Colombia.
Rheumatology (Oxford) ; 2024 Mar 02.
Article en En | MEDLINE | ID: mdl-38430474
ABSTRACT

OBJECTIVES:

To explore prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIM) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.

METHODS:

A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after 2 vaccine doses. We compared BIs characteristics and severity among IIMs, other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HC). Multivariable Cox regression models assessed the risk factors for BI, severe BI and hospitalisations among IIMs.

RESULTS:

Among 9449 included response, BIs occurred in 1447 (15.3%) respondents, median age 44 years (IQR 21), 77.4% female, and 182 BIs (12.9%) occurred among 1406 IIMs. Multivariable Cox regression among IIMs showed age as a protective factor for BIs [Hazard Ratio (HR)=0.98, 95%CI = 0.97-0.99], hydroxychloroquine and sulfasalazine use were risk factors (HR = 1.81, 95%CI = 1.24-2.64, and HR = 3.79, 95%CI = 1.69-8.42, respectively). Glucocorticoid use was a risk factor for severe BI (HR = 3.61, 95%CI = 1.09-11.8). Non-White ethnicity (HR = 2.61, 95%CI = 1.03-6.59) was a risk factor for hospitalisation. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIM = 6.0% vs AIRD = 1.8%, nrAID = 2.2%, and HC = 0.9%), intensive care unit admission (IIM = 2.2% vs AIRD = 0.6%, nrAID, and HC = 0%), advanced treatment with antiviral or monoclonal antibodies (IIM = 34.1% vs AIRD = 25.8%, nrAID = 14.6%, and HC = 12.8%), and had more hospitalisation (IIM = 7.7% vs AIRD = 4.6%, nrAID = 1.1%, and HC = 1.5%).

CONCLUSION:

Patients with IIMs are susceptible to severe COVID-19 BI. Age and immunosuppressive treatments were related to the risk of BIs.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil